PNH is not an inherited disease, but it is caused by a change, or mutation, in the PIGA gene. The PIGA gene codes for an enzyme needed to make a chemical that helps anchor proteins to the cell ...

Ruxoprubart (NM8074) met all clinical endpoints, offering a safe, differentiated treatment for Paroxysmal Nocturnal ...

In people with PNH, part of your immune system targets abnormal red blood cells, breaking apart those cells. This happens when a gene (called PIGA) mutates in the bone marrow’s stem cells.

NovelMed announce positive 12-week interim results from phase II trial of Ruxoprubart in adult patients with PNH: Cleveland Wednesday, May 21, 2025, 12:00 Hrs [IST] NovelMed, a cl ...

China has become the first country in the world to approve Roche’s anti-complement C5 antibody crovalimab, the only treatment for the rare disorder paroxysmal nocturnal haemoglobinuria (PNH ...

Key opinion leaders navigate barriers to optimal care for patients receiving treatment for PNH. June 11th 2024EP. 4: Key Treatment Considerations for Patients Diagnosed With PNH Dr Haumschild ...

Findings from a post hoc analysis of 3 clinical trials support the switching to or initiation of pegcetacoplan to manage fatigue for patients with paroxysmal nocturnal hemoglobinuria (PNH ...

PNH is a rare, acquired hematologic disorder in which Red Blood Cells lack protective surface proteins due to a mutation in the phosphatidylinositol glycan class A (PIGA) gene, leaving them ...

PNH is a rare, acquired hematologic disorder in which Red Blood Cells lack protective surface proteins due to a mutation in the phosphatidylinositol glycan class A (PIGA) gene, leaving them ...

Ruxoprubart (NM8074) met all clinical endpoints, offering a safe, differentiated treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH). CLEVELAND, May 19, 2025 (GLOBE NEWSWIRE) -- NovelMed is ...